Icon

XYZAL (nda022064)- (5MG)

LEVOCETIRIZINE DIHYDROCHLORIDE CHATTEM SANOFI
5MG
Yes Yes
2014-Jan-26 Expired
None None
None No
XYZAL is a histamine H1-receptor antagonist indicated for: • The relief of symptoms associated with perennial allergic rhinitis. • The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria.
9 0 8
Total Other Developers 2
Drugs with Suitability No
5MG ** ** - - 6
NDA Sales Available Total Generic Sales Available
No 7
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* ****** ********** ****** **** *********** *********** ******* **-**, **********, *****, ******* (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** ** *-*, ******* ********** ******, *******-******,, ***, ** ******, ***** (***) ***
****** ** ****** **** *** **. *****'* ************ ******* *********** ****** **. **, ** ****, ** **** & ** ****, ********** ******* *** ******, *******-********** ********,, *******-**********, ********* ******, ***** (***) ***
****** ****** **** *** *** ****** **** ******* *********** **** ***, **** **. **-***, ****-**, ***, **********, *********, ********* ******, ***** (***) ***
****** ****** **** *** *** ****** ****** ******* ******* *********** ****** **. ***, ******* *******, *********** ******,, **********, ********* ******, ***** (***) ***
****** ***** **** *** ***** ***** **** ******* *********** **** **. *-*** ** *-*** & **, ***** *** & ***** **, ***** ********** ******, *****, *** ******, ***** (***) ***
****** ******* ****** *** ******* ***************, ***. *********** ** ***** *****, *********, *** **** (**) *****-****, ****** ****** (***) ***
****** ******** ****** *** ******** *************** ******* *********** ******* *****, **** ****** **********,****** *****, ******** *****, ******** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.